Current Hypertension Reports

Hypertension Across a Woman’s Life Cycle.  24:723-733. 2022

Cardiovascular Disease Risk Reduction and Body Mass Index.  24:535-546. 2022

Integrated Care Model of Adiposity-Related Chronic Diseases.  24:563-570. 2022

Migrating Populations and Health: Risk Factors for Cardiovascular Disease and Metabolic Syndrome.  24:325-340. 2022

Pet Ownership and the Risk of Arterial Hypertension and Cardiovascular Disease.  24:295-302. 2022

An Update on Refractory Hypertension.  24:225-234. 2022

Coffee and Arterial Hypertension.  23. 2021

Response to “Comment’s on the Story of the Silent Killer, a History of Hypertension: Its Discovery, Diagnosis, Treatment, and Debate”.  23. 2021

Prevention, Diagnosis, and Management of Hypertensive Disorders of Pregnancy: a Comparison of International Guidelines.  22. 2020

The Story of the Silent Killer: A History of Hypertension: Its Discovery, Diagnosis, Treatment, and Debates.  22. 2020

Weight Reduction for Obesity-Induced Heart Failure with Preserved Ejection Fraction.  22. 2020

Obesity, Hypertension, and Bariatric Surgery.  22. 2020

State of the Art: the Not-So-Great Wall of America.  21. 2019

Epicardial Adipose Tissue and Cardiovascular Disease.  21. 2019

Unanswered Questions Regarding Blood Pressure Management for HF Prevention.  21. 2019

Obesity and Pulmonary Hypertension.  20. 2018

Out of Office Blood Pressure Measurement in Pregnancy and the Postpartum Period.  20. 2018

Novel Medical Treatments for Hypertension and Related Comorbidities.  20. 2018

Visceral Adipose Tissue Accumulation and Residual Cardiovascular Risk.  20. 2018

A Systematic Review of Sleep, Hypertension, and Cardiovascular Risk in Children and Adolescents.  20. 2018

Masked Hypertension.  19. 2017

Regression of Left Ventricular Mass After Bariatric Surgery.  19. 2017

Sex-Specific Contributions of Endothelin to Hypertension.  20. 2017

Isometric Handgrip as an Adjunct for Blood Pressure Control: a Primer for Clinicians.  19. 2017

Obesity-Associated Hypertension: the Upcoming Phenotype in African-American Women.  19. 2017

Novel Cardiac Intracrine Mechanisms Based on Ang-(1-12)/Chymase Axis Require a Revision of Therapeutic Approaches in Human Heart Disease.  19. 2017

Pathophysiology and Potential Non-Pharmacologic Treatments of Obesity or Kidney Disease Associated Refractory Hypertension.  19. 2017

Sleep Disordered Breathing: Hypertension and Cardiac Structure and Function.  17. 2015

Mechanisms Influencing Circadian Blood Pressure Patterns Among Individuals with HIV.  17. 2015

Inflammation and Hypertension: New Understandings and Potential Therapeutic Targets.  17. 2014

Alterations in cardiac structure and function in hypertension.  16. 2014

Angiotensin-(1-12): A chymase-mediated cellular angiotensin II substrate.  16. 2014

Therapy of acute hypertension in hospitalized children and adolescents.  16. 2014

Vitamin D deficiency in the pathogenesis of hypertension: Still an unsettled question.  16. 2014

Mechanisms of lipotoxicity in the cardiovascular system.  14:517-531. 2012

Epidemiology of obesity, the metabolic syndrome, and chronic kidney disease.  14:152-159. 2012

Vitamin D therapy and cardiovascular health.  13:187-191. 2011

A stitch saves time and lowers blood pressure.  12:146-148. 2010

Heme oxygenase and renal disease.  11:56-62. 2009

Beyond brachial pressure effect..  10:213-215. 2008

Neurohormonal regulation of the sympathetic nervous system: New insights into central mechanisms of action.  10:233-240. 2008

Leptin and mechanisms of endothelial dysfunction and cardiovascular disease..  10:434-439. 2008

Are current guidelines optimal for treatment of blood pressure in patients with coronary artery disease?.  9:211-213. 2007

Uric acid and hypertension.  8:111-115. 2006

Circadian rhythms in cardiac gene expression.  5:445-453. 2003

Effects of hormone replacement therapy on the sympathetic nervous system and blood pressure.  5:241-246. 2003

Do angiotensin receptor antagonists have benefits beyond blood pressure lowering?.  4:219-220. 2002

Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs.  3:227-228. 2001

Health outcomes associated with calcium antagonists.  3:228-229. 2001

The role of the nervous system in hypertension.  3:255-262. 2001

Aldosterone-related genetic effects in hypertension.  2:295-301. 2000

Antihypertensive drug therapy in the third millennium: Are there benefits beyond blood pressure?.  2:291-294. 2000

Recent outcome trials of newer antihypertensives.  1:238-240. 1999

The epithelial sodium channel in hypertension.  1:158-163. 1999

The role of the central nervous system in hypertension.  1:246-253. 1999